Stage D2前立腺癌の長期生存例の予後因子の検討

Abstract

1971年より1987年までに千葉大学泌尿器科において内分泌療法を施行したstage D2前立腺癌175例のうち, 5年以上制癌状態のもの18例と, 治療に反応せず, あるいは当初制癌されたが再燃し3年以内に癌死したもの35例との宿主側, 腫瘍側因子の比較を行った.両群間に有意差を認めたものは, 骨疼痛, 貧血, 組織学的分化度, 骨転移の拡がり, 内分泌療法の反応性であった

To clarify factors affecting prognosis following endocrine therapy, stage D2 patients who died from prostatic cancer within 3 years and those under well-controlled state longer than 5 years were compared with respect to background factors and response to endocrine therapy. Thirty-five and 18 cases, respectively, were studied. Differences between the two groups were bone pain, anemia, tumor grade, number of bone metastasis, and response to endocrine therapy. Performance status in long-term survival groups tended to be better than that in short-term cancer death groups.